Evaluation of the effects of Coenzyme Q10 on the serum concentration of interleukin 6 and interleukin 33 in hemodialysis patients
Not Applicable
- Conditions
- End Stage Renal Disease (Hemodialysis).Chronic kidney disease, stage 5 Chronic uraemia End stage kidney disease: in allograft failure NOS on dialysis without dialysis or transplant
- Registration Number
- IRCT2015061722637N2
- Lead Sponsor
- Vice chancellor for research, Kerman University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
Patients who are undergoing regular hemodialysis for at least 3 months will be entered.
Exclusion criteria: Being in active infection phase, having autoimmune diseases, consuming immunosuppressive medications or warfarin, pregnancy, breast feeding
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum concentration of interleukin 6. Timepoint: At baseline and at the end of the study. Method of measurement: ELISA kit.;Serum concentration of interleukin 33. Timepoint: At baseline and at the end of the study. Method of measurement: ELISA kit.
- Secondary Outcome Measures
Name Time Method Adverse effects. Timepoint: During the study. Method of measurement: Patients' report.